Cargando…

Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

SIMPLE SUMMARY: Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Agnete Witness Praest, Carnaz Simões, Ana Micaela, thor Straten, Per, Holmen Olofsson, Gitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866099/
https://www.ncbi.nlm.nih.gov/pubmed/33494360
http://dx.doi.org/10.3390/cancers13030394
_version_ 1783648002057961472
author Jensen, Agnete Witness Praest
Carnaz Simões, Ana Micaela
thor Straten, Per
Holmen Olofsson, Gitte
author_facet Jensen, Agnete Witness Praest
Carnaz Simões, Ana Micaela
thor Straten, Per
Holmen Olofsson, Gitte
author_sort Jensen, Agnete Witness Praest
collection PubMed
description SIMPLE SUMMARY: Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combination with immunotherapy. Strikingly, administration of β-blockers—which block the effect of adrenaline/noradrenaline—are also suggested to be useful in cancer therapy alone or in combination with immunotherapy. Herein we discuss the question of whether exercise and the administration of β-blockers could potentially be useful in cancer therapy. ABSTRACT: The incidence of cancer is increasing worldwide, which is to a large extent related to the population’s increasing lifespan. However, lifestyle changes in the Western world are causative as well. Exercise is intrinsically associated with what one could call a “healthy life”, and physical activity is associated with a lower risk of various types of cancer. Mouse models of exercise have shown therapeutic efficacy across numerous cancer models, at least in part due to the secretion of adrenaline, which mobilizes cells of the immune system, i.e., cytotoxic T and natural killer (NK) cells, through signaling of the β-2 adrenergic receptor (β2AR). Clinical trials aiming to investigate the clinical value of exercise are ongoing. Strikingly, however, the use of β-blockers—antagonists of the very same signaling pathway—also shows signs of clinical potential in cancer therapy. Cancer cells also express β-adrenergic receptors (βARs) and signaling of the receptor is oncogenic. Moreover, there are data to suggest that β2AR signaling in T cells renders the cell functionally suppressed. In this paper, we discuss these seemingly opposing mechanisms of cancer therapy—exercise, which leads to increased β2AR signaling, and β-blocker treatment, which antagonizes that same signaling—and suggest potential mechanisms and possibilities for their combination.
format Online
Article
Text
id pubmed-7866099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78660992021-02-07 Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Jensen, Agnete Witness Praest Carnaz Simões, Ana Micaela thor Straten, Per Holmen Olofsson, Gitte Cancers (Basel) Review SIMPLE SUMMARY: Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combination with immunotherapy. Strikingly, administration of β-blockers—which block the effect of adrenaline/noradrenaline—are also suggested to be useful in cancer therapy alone or in combination with immunotherapy. Herein we discuss the question of whether exercise and the administration of β-blockers could potentially be useful in cancer therapy. ABSTRACT: The incidence of cancer is increasing worldwide, which is to a large extent related to the population’s increasing lifespan. However, lifestyle changes in the Western world are causative as well. Exercise is intrinsically associated with what one could call a “healthy life”, and physical activity is associated with a lower risk of various types of cancer. Mouse models of exercise have shown therapeutic efficacy across numerous cancer models, at least in part due to the secretion of adrenaline, which mobilizes cells of the immune system, i.e., cytotoxic T and natural killer (NK) cells, through signaling of the β-2 adrenergic receptor (β2AR). Clinical trials aiming to investigate the clinical value of exercise are ongoing. Strikingly, however, the use of β-blockers—antagonists of the very same signaling pathway—also shows signs of clinical potential in cancer therapy. Cancer cells also express β-adrenergic receptors (βARs) and signaling of the receptor is oncogenic. Moreover, there are data to suggest that β2AR signaling in T cells renders the cell functionally suppressed. In this paper, we discuss these seemingly opposing mechanisms of cancer therapy—exercise, which leads to increased β2AR signaling, and β-blocker treatment, which antagonizes that same signaling—and suggest potential mechanisms and possibilities for their combination. MDPI 2021-01-21 /pmc/articles/PMC7866099/ /pubmed/33494360 http://dx.doi.org/10.3390/cancers13030394 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jensen, Agnete Witness Praest
Carnaz Simões, Ana Micaela
thor Straten, Per
Holmen Olofsson, Gitte
Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title_full Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title_fullStr Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title_full_unstemmed Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title_short Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
title_sort adrenergic signaling in immunotherapy of cancer: friend or foe?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866099/
https://www.ncbi.nlm.nih.gov/pubmed/33494360
http://dx.doi.org/10.3390/cancers13030394
work_keys_str_mv AT jensenagnetewitnesspraest adrenergicsignalinginimmunotherapyofcancerfriendorfoe
AT carnazsimoesanamicaela adrenergicsignalinginimmunotherapyofcancerfriendorfoe
AT thorstratenper adrenergicsignalinginimmunotherapyofcancerfriendorfoe
AT holmenolofssongitte adrenergicsignalinginimmunotherapyofcancerfriendorfoe